Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of Part B is to compare the PFS of ramucirumab administered in combination with erlotinib versus placebo in combination with erlotinib in previously untreated patients with EGFR mutation-positive metastatic NSCLC.
Critère d'inclusion
- EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer